The Peripheral and Central Nervous System Drugs Advisory Committee discusses Biogen’s New Drug Application (NDA) 215887 for Tofersen (BIIB067) Intrathecal injection for treatment of amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene in a virtual meeting to be held on March 22 at 9:15 am. Webcast Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BIIB:
- Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
- Inozyme appoints Matthew Winton as COO
- FDA Peripheral/Central Nervous System Drugs Advisory Committee holds meeting
- FDA briefing docs suggest FDA in favor of Biogen’s tofersen, says BofA
- FDA posts briefing document for advisors’ review of Biogen’s ALS drug